Can B Corp (CANB)

[Penny Masters]

Your excited about the 12 million in losses? Too funny this bullshit charade goes on.

Wonder what the next sector CANB will be in as they failed miserably in this sector.

Peace out

[skyhawk66]

So Exiting, CANB has got its Investors on the Edge. Who can blame, 3rd Record Quarter Fast Approaches :) $$$$

In the meantime…..Accumulation Continues Daily,Weekly, And Monthly….Period.

[waterchaser]

Yep, it's hard to look away at a train wreck like CANB.

[skyhawk66]

Couldn’t Agree more BG, spot on.

Glad I’m loading Up along with others at these discounted levels.

In the mean time, All Eyes remain laser focused on CANB $$$

[badguy3101]

Calm, cool and collected. I know the ENTIRE sector is down and has been for over 2 years so any bad talk is just bullshit rhetoric.

CANB

NASDAQ



The Badguy

[waterchaser]

Key Financial Highlights for Q3 2022:
CANB LOSS FOR 9 mos 2022 ~ $12,024,759.
(that’s 12 MILLION DOLLARS)

[skyhawk66]

Wow! You called it. CANB Up 35% today on Solid Buying Volume!
Accumulation Continues!
Facts will Always beat limited laughable going out of business opinion.
All Eyes Continue to Watch CANB Daily as 3rd Record Breaking Quarter Fast Approaches $$$$$

CANB…..2023 Blastoff Year $$$$

[cfoofme]

“More to come indeed !”. You mean just like 2022 when PPS plummeted from $6 to $1.25 ???

[waterchaser]

Yep, things aren’t as rosy with CANB as some want us to believe.

[Penny Masters]

CANB LOST 12 MILLION IN A SINGLE Q. Nasty with the bloated salaries and products few want.

Peace out

[waterchaser]

Key Financial Highlights for Q3 2022:
CANB LOSS FOR 9 mos 2022 ~ $12,024,759.
(that’s 12 MILLION DOLLARS)

[waterchaser]

Sure glad I didn’t invest all my winnings from a different OTC scam into CANB.

It would really suck to lose it all to this overhyped CANB charade.
What a loser CANB has turned out to be.

[skyhawk66]

Spot ON BG, Patience and Vision. Let’s not forget Record Breaking Quarters back to back :)
:
More to come indeed! Again, I make money and CANB will be another money maker. Ex: my photo below was taken in October 2016. As you can see I have 3MIL shares of RXM*. Purchased those shares at .005
In March 2018 I sold all 3MIL shares between .18 and .21
Made over $600,000 PROFIT!
It was a very nice feeling!
VERY NICE! LOL!!!! Awwww

Anyhow, same will happen with CANB

VISION

PATIENCE

CANB

[badguy3101]

More to come indeed! Again, I make money and CANB will be another money maker. Ex: my photo below was taken in October 2016. As you can see I have 3MIL shares of RXM*. Purchased those shares at .005
In March 2018 I sold all 3MIL shares between .18 and .21
Made over $600,000 PROFIT!
It was a very nice feeling!
VERY NICE! LOL!!!! Awwww

Anyhow, same will happen with CANB

VISION

PATIENCE

CANB




The Badguy

[Penny Masters]

You forgot,,, 12 million in losses that Q. Maybe some need to know when the fat lady sang, Elvis left the building and simply put,,, game over Man.

Happy New Year and glad this one is finally Kaput.

Peace out

[skyhawk66]

CANB UP 25% on Heavy Accumulation, goes to show train wreck opinion is very limited and more of a Joke.
CANB headed for a 3rd Quarter Record Earning is taken very serious by Investors who are holding on to their shares with a Kung Fu Grip.
Very Exciting to see what 2023 and Beyond hold for this New Gem.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170519939

[Penny Masters]

Good luck Skyhawk as this trainwreck is over. The longs cannot sell as they have no value and CANB has fallen after multi RS's and will never ever get back up.

Have a good 2023 and hope the losses were not too great on this OTC cesspool play.

Peace out

[skyhawk66]

Hmm, misleading Again IMO, Facts Now, CANB Monthly Chart And Continued Quarterly Record Breakers Don’t Lie.
Up Again today almost 8% as investors continue to Load at these Oversold levels.

CANB- 2023 and Beyond Easily….Period

[Penny Masters]

Not sure CANB can do a 3rd RS. The past few killed the value and I think the real value adjusted for all the RS's is now .000's. CANB fallen and cannot get up.

Some cannot handle the truth they been duped. These sleek salesman type OTC cesspool plays know how to take the money and run.

Peace out

[skyhawk66]

Correct, much more to come for CANB. Up almost 25% yesterday and today almost 8% intra day.
So much for the fake doom and gloom limited opinion, lol.
Smart Money Will keep Accumulating at these oversold prices all day long.
3rd Straight Quarter with Record Earnings fast Approaching and No One wants to be left behind…Period.

CANB….2023 and Beyond

[skyhawk66]

Wow, Volume of over 20k today, mostly Buys! Averaging 25% Gain so far!
Sooo Exciting! Glad All CANB Followers are watching Daily!

CANB…2023 and Beyond.

3rd Record Quarter Approaches and No one wants to be left Behind :)

[waterchaser]

More losses? Yikes, has CANB ever been a disaster!
One of the worst OTC’s I’ve ever seen, and I’ve followed a lot.

Considering the reverse splits, what’s the actual PPS value of this garbage?

Thanks.

Much more to come

[badguy3101]

Much more to come

CANB

NASDAQ



The Badguy

[skyhawk66]

Actually almost 20% up so far today.
So much for the going out of business fiasco that’s been played out 4 years ago.
Goes to show Accumulation Continues
weekly and Monthly by new Investors.
Patience is Key and understood.

CANB…2023 and Beyond

[waterchaser]

Below a dollar today?

[Penny Masters]

CANB record breaking losses. LOLOLOL They are done and all know it. A few still try to sugar coat a turd.

Peace out

[waterchaser]

Key Financial Highlights for Q3 2022:
CANB LOSS FOR 9 mos 2022 ~ $12,024,759.
(that’s 12 MILLION DOLLARS)

[skyhawk66]

CANB breaks Another Quarterly Record back to back. See Sticky Factual Information.
Looks like the misleading Opinion of going out of business or. Losing their doors has been played out 4 years ago, lol.
No wonder investors are holding on to their shares with a Kung Fu Grip.
:
As Forecasted, Another Record Quarterly Revenue Record for CANB!
Can B Corp. Reports Growth of 51% to $2.9 Million Revenue for Third Quarter 2022, the Highest Quarterly Revenue in Company History

Can B Corp
Tue, November 22, 2022 at 9:30 AM
In this article:

Can B Corp

Led by a Significant Increase in Duramed, Music City Botanical and Botanical Biotech Brands

Adjusted EBITDA Loss Decreased by 25% to $1.5 Million

HICKSVILLE, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company's financial results for the third quarter and nine months ended September 30, 2022.

Key Financial Highlights for Q3 2022

Revenue increased 51% to $2.9 million

Gross profit increased 36% to $1.9 million

Gross margin decreased to 64.3%

Adjusted EBITDA loss decreased by 25% to $1.5 million

Accounts receivable at $7.0 million

Inventory at $2.3 million

Total assets at $16.7 million

Total stockholders’ equity at $4.5 million

Key Financial Highlights for 9 Months Ended September 30, 2022

Revenue increased 130% to $6.0 million

Gross profit increased 59% to $2.8 million

Gross margin decreased to 46.0%

Adjusted EBITDA loss decreased by 15% to $4.5 million

[Penny Masters]

Can you say MASSIVE TRAIN WRECK for CANB! What a nightmare as all share holder value is gone and they look like it may be game over as it approached 1.00. After multi RS's this thing goes to nothing again for the 3rd time.

Shows you how the OTC cesspool really works and what it is for.

Peace out

[Penny Masters]

NOBODY, NADDA, NILL made any money on CANB PIG besides the insiders that dumped shares after every RS. PERIOD, mark it and game over!

It was a sleek scheme that was pulled and all can easily see what they did and how.

Peace out

[waterchaser]

CANB LOSS FOR 9 mos 2022 $12,024,759.
(that’s 12 MILLION DOLLARS)

[skyhawk66]

Excellent Track Record, Correct about CANB being a future Major player. No wonder Smart Money Keeps Accumulating on these Dips. Who can blame them,…
Record Back to Back Quarterly Earnings speaks for itself.
New Investors see below:

As Forecasted, Another Record Quarterly Revenue Record for CANB!
Can B Corp. Reports Growth of 51% to $2.9 Million Revenue for Third Quarter 2022, the Highest Quarterly Revenue in Company History

Can B Corp
Tue, November 22, 2022 at 9:30 AM
In this article:

Can B Corp

Led by a Significant Increase in Duramed, Music City Botanical and Botanical Biotech Brands

Adjusted EBITDA Loss Decreased by 25% to $1.5 Million

HICKSVILLE, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company's financial results for the third quarter and nine months ended September 30, 2022.

Key Financial Highlights for Q3 2022

Revenue increased 51% to $2.9 million

Gross profit increased 36% to $1.9 million

Gross margin decreased to 64.3%

Adjusted EBITDA loss decreased by 25% to $1.5 million

Accounts receivable at $7.0 million

Inventory at $2.3 million

Total assets at $16.7 million

Total stockholders’ equity at $4.5 million

Key Financial Highlights for 9 Months Ended September 30, 2022

Revenue increased 130% to $6.0 million

Gross profit increased 59% to $2.8 million

Gross margin decreased to 46.0%

Adjusted EBITDA loss decreased by 15% to $4.5 million

Key Business Highlights for Q3 2022

Signed Manufacturing and Distribution Agreement for Superfood Products with Forever Brands and Brooke Burke via BB Body, Inc.

Consolidated Hemp Division Operations in Colorado

Management Commentary

Marco Alfonsi, Can B’s Chief Executive Officer, stated, “We are thrilled with our tremendous quarterly results, having achieved the highest quarterly revenue in our company history. We generated $2.9 million in quarterly revenue while reducing our cash burn as demonstrated by the 25% decrease in Adjusted EBITDA. Our team made great strides over the past several months integrating and ramping up the various operations we strategically acquired over the past year to complete our vertical processing capabilities.”

Alfonsi concluded, “We had a vision and were confident in the assets we were assembling over the past year. It is great to see all the challenging work pay off and result in accelerating revenue growth and a reduction in cash losses. With our proven manufacturing and distribution capabilities, we are now executing major strategic agreements, such as the recently announced deal with Brooke Burke. Since the end of the quarter, we have started taking orders and shipping Superfood Products with Brooke Burke and are very excited about the early demand and results. Can B is now a full-service hemp-derived cannabinoid company that can facilitate servicing large box retailers, boutique vape and smoke stores, and strategic partners.”

Manufacturing and Distribution Agreement for Superfoods Products with Forever Brands and Brooke Burke via BB Body, Inc.

The initial 3-year worldwide agreement covers the sale, manufacturing, and distribution of Superfoods and related nutritional products. Can B subsidiaries Imbibe Wellness Solutions is the exclusive direct-to-consumer seller of the products and Pure Health Products is a manufacturer and distributor of the products. The products will be marketed under the Longevity by Brooke Burke trademarks and brand. The partnership includes a powdered drink superfood mix, an all-natural metabolic energy drink, and other products that may be mutually agreed from time to time.

Brooke Burke, an American television personality, fitness personality, author, actress, and businessperson, will market, endorse, and promote the products as a monthly online subscription model under her company BB Body, Inc.

Subsequent to the end of the third quarter, the product launched.

Financial Results for the Three Months Ended September 30, 2021:

Revenue: For the three months ended September 30, 2022, revenue was $2.9 million, an increase of $1.0 million, or 51%, compared with $1.9 million for the three months ended September 30, 2021. The increase is due to the ` winddown of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound devices associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase of sales compared to 2021 of approximately $1.5 million.

Gross Profit: For the three months ended September 30, 2022, gross profit was $1.9 million, an increase of $0.5 million, or 36%, compared with $1.4 million for the three months ended September 30, 2021. The resulting gross margin was 64.3%, compared with 71.7% for the same quarter last year.

Total Operating Expenses: For the three months ended September 30, 2022, total operating expenses were $8.7 million, an increase of $4.8 million, or 223%, compared with $3.9 million for the same quarter last year. The increase in operating expenses was primarily due to the non-cash stock-based compensation expense of $4.5 million and $0.8 million of other non-cash and non-recurring one-time items.

Operating Loss: For the three months ended September 30, 2022, operating loss was $6.8 million, an increase of $4.3 million, or 271%, compared with an operating loss of $2.5 million for the same quarter last year.

Adjusted EBITDA Loss: For the three months ended September 30, 2022, Adjusted EBITDA loss was $1.5 million, a decrease of $0.5 million, or 25%, compared with an Adjusted EBITDA loss of $2.0 million for the same period last year, after deducting non-cash and one-time expenses.

Net Loss: For the three months ended September 30, 2022, the net loss was $6.9 million, or ($1.98) per share, compared with a net loss of $3.2 million, or a net loss of ($1.61) per share, for the three months ended September 30, 2021.

Financial Results for the Nine Months Ended September 30, 2022:

Revenue: For the nine months ended September 30, 2022, revenue was $6.0 million, an increase of $3.4 million, or 130%, compared with $2.6 million for the same period last year. The increase is due to the winddown of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound devices associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase of sales compared to 2021 of approximately $2.2 million.

Gross Profit: For the nine months ended September 30, 2022, gross profit was $2.8 million, an increase of $1.0 million, or 59%, compared with $1.7 million for the same period last year. The resulting gross margin was 46%, compared with 66% for the same period last year.

Total Operating Expenses: For the nine months ended September 30, 2022, total operating expenses were $14.3 million, an increase of $5.7 million, or 243%, compared with $8.6 million for the same period last year. The increase in operating expenses was primarily due to the non-cash stock-based compensation expense of $5.1 million.

Operating Loss: For the nine months ended September 30, 2022, operating loss was $11.6 million, an increase of $4.7 million, compared with an operating loss of $6.9 million for the same period last year.

Adjusted EBITDA Loss: For the nine months ended September 30, 2022, Adjusted EBITDA loss was $4.5 million, a decrease of $0.8 million, or 15%, compared with an Adjusted EBITDA loss of $5.3 million for the same period last year, after deducting non-cash and one-time expenses.

Net Loss: For the nine months ended September 30, 2022, net loss was $12.0 million, or ($3.56) per share, compared with $8.2 million, or ($5.39) per share, for the same period last year.

About Can B Corp.

Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp-derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high-quality products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

Facebook @ Can B Corp

[waterchaser]

CANB is dead money.

[badguy3101]

Again, I make money and CANB will be another money maker. Ex: my photo below was taken in October 2016. As you can see I have 3MIL shares of RXM*. Purchased those shares at .005
In March 2018 I sold all 3MIL shares between .18 and .21
Made over $600,000 PROFIT!
It was a very nice feeling!
VERY NICE! LOL!!!! Awwww

Anyhow, same will happen with CANB

VISION

PATIENCE

CANB



The BADGUY!!!!

[Penny Masters]

Looks like CANB "going below 1.00", is coming soon. There true value will soon be under .0001 and not sure how they are allowed to continue with RS's.


Peace out

[waterchaser]

Another REVERSE SPLIT when PPS goes below $1?

[waterchaser]

How many CANB REVERSE SPLITS have there been?

[waterchaser]

How much did CANB lose during the last 9 months?

[badguy3101]

I make money and CANB will be another money maker. Ex: my photo below was taken in October 2016. As you can see I have 3MIL shares of RXM*. Purchased those shares at .005
In March 2018 I sold all 3MIL between .18 and .21
Made over $600,000 PROFIT!
It was a very nice feeling!
VERY NICE! LOL!!!! Awwww

Anyhow, same will happen with CANB

VISION

PATIENCE

CANB



The BADGUY!!!!

[Penny Masters]

CANB lost another 12 million past 9 months. NASTY and looks like another RS may be needed as this tanks for the 3rd time.

Peace out

[waterchaser]

How much did they lose during the last 9 months?

[badguy3101]

Can B Corp. Reports Growth of 51% to $2.9 Million Revenue for Third Quarter 2022, the Highest Quarterly Revenue in Company History

Press Release | 11/22/2022

Led by a Significant Increase in Duramed, Music City Botanical and Botanical Biotech Brands

Adjusted EBITDA Loss Decreased by 25% to $1.5 Million

HICKSVILLE, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company's financial results for the third quarter and nine months ended September 30, 2022.

Key Financial Highlights for Q3 2022

Revenue increased 51% to $2.9 million
Gross profit increased 36% to $1.9 million
Gross margin decreased to 64.3%
Adjusted EBITDA loss decreased by 25% to $1.5 million
Accounts receivable at $7.0 million
Inventory at $2.3 million
Total assets at $16.7 million
Total stockholders’ equity at $4.5 million
Key Financial Highlights for 9 Months Ended September 30, 2022

Revenue increased 130% to $6.0 million
Gross profit increased 59% to $2.8 million
Gross margin decreased to 46.0%
Adjusted EBITDA loss decreased by 15% to $4.5 million
Key Business Highlights for Q3 2022

Signed Manufacturing and Distribution Agreement for Superfood Products with Forever Brands and Brooke Burke via BB Body, Inc.
Consolidated Hemp Division Operations in Colorado
Management Commentary

Marco Alfonsi, Can B’s Chief Executive Officer, stated, “We are thrilled with our tremendous quarterly results, having achieved the highest quarterly revenue in our company history. We generated $2.9 million in quarterly revenue while reducing our cash burn as demonstrated by the 25% decrease in Adjusted EBITDA. Our team made great strides over the past several months integrating and ramping up the various operations we strategically acquired over the past year to complete our vertical processing capabilities.”

Alfonsi concluded, “We had a vision and were confident in the assets we were assembling over the past year. It is great to see all the challenging work pay off and result in accelerating revenue growth and a reduction in cash losses. With our proven manufacturing and distribution capabilities, we are now executing major strategic agreements, such as the recently announced deal with Brooke Burke. Since the end of the quarter, we have started taking orders and shipping Superfood Products with Brooke Burke and are very excited about the early demand and results. Can B is now a full-service hemp-derived cannabinoid company that can facilitate servicing large box retailers, boutique vape and smoke stores, and strategic partners.”

Manufacturing and Distribution Agreement for Superfoods Products with Forever Brands and Brooke Burke via BB Body, Inc.

The initial 3-year worldwide agreement covers the sale, manufacturing, and distribution of Superfoods and related nutritional products. Can B subsidiaries Imbibe Wellness Solutions is the exclusive direct-to-consumer seller of the products and Pure Health Products is a manufacturer and distributor of the products. The products will be marketed under the Longevity by Brooke Burke trademarks and brand. The partnership includes a powdered drink superfood mix, an all-natural metabolic energy drink, and other products that may be mutually agreed from time to time.

Brooke Burke, an American television personality, fitness personality, author, actress, and businessperson, will market, endorse, and promote the products as a monthly online subscription model under her company BB Body, Inc.

Subsequent to the end of the third quarter, the product launched.

Financial Results for the Three Months Ended September 30, 2021:

Revenue: For the three months ended September 30, 2022, revenue was $2.9 million, an increase of $1.0 million, or 51%, compared with $1.9 million for the three months ended September 30, 2021. The increase is due to the ` winddown of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound devices associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase of sales compared to 2021 of approximately $1.5 million.
Gross Profit: For the three months ended September 30, 2022, gross profit was $1.9 million, an increase of $0.5 million, or 36%, compared with $1.4 million for the three months ended September 30, 2021. The resulting gross margin was 64.3%, compared with 71.7% for the same quarter last year.
Total Operating Expenses: For the three months ended September 30, 2022, total operating expenses were $8.7 million, an increase of $4.8 million, or 223%, compared with $3.9 million for the same quarter last year. The increase in operating expenses was primarily due to the non-cash stock-based compensation expense of $4.5 million and $0.8 million of other non-cash and non-recurring one-time items.
Operating Loss: For the three months ended September 30, 2022, operating loss was $6.8 million, an increase of $4.3 million, or 271%, compared with an operating loss of $2.5 million for the same quarter last year.
Adjusted EBITDA Loss: For the three months ended September 30, 2022, Adjusted EBITDA loss was $1.5 million, a decrease of $0.5 million, or 25%, compared with an Adjusted EBITDA loss of $2.0 million for the same period last year, after deducting non-cash and one-time expenses.
Net Loss: For the three months ended September 30, 2022, the net loss was $6.9 million, or ($1.98) per share, compared with a net loss of $3.2 million, or a net loss of ($1.61) per share, for the three months ended September 30, 2021.
Financial Results for the Nine Months Ended September 30, 2022:

Revenue: For the nine months ended September 30, 2022, revenue was $6.0 million, an increase of $3.4 million, or 130%, compared with $2.6 million for the same period last year. The increase is due to the winddown of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound devices associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase of sales compared to 2021 of approximately $2.2 million.
Gross Profit: For the nine months ended September 30, 2022, gross profit was $2.8 million, an increase of $1.0 million, or 59%, compared with $1.7 million for the same period last year. The resulting gross margin was 46%, compared with 66% for the same period last year.
Total Operating Expenses: For the nine months ended September 30, 2022, total operating expenses were $14.3 million, an increase of $5.7 million, or 243%, compared with $8.6 million for the same period last year. The increase in operating expenses was primarily due to the non-cash stock-based compensation expense of $5.1 million.
Operating Loss: For the nine months ended September 30, 2022, operating loss was $11.6 million, an increase of $4.7 million, compared with an operating loss of $6.9 million for the same period last year.
Adjusted EBITDA Loss: For the nine months ended September 30, 2022, Adjusted EBITDA loss was $4.5 million, a decrease of $0.8 million, or 15%, compared with an Adjusted EBITDA loss of $5.3 million for the same period last year, after deducting non-cash and one-time expenses.
Net Loss: For the nine months ended September 30, 2022, net loss was $12.0 million, or ($3.56) per share, compared with $8.2 million, or ($5.39) per share, for the same period last year.
About Can B Corp.

Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp-derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high-quality products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

Facebook @ Can B Corp

YouTube



NASDAQ


The Badguy

[waterchaser]

Reverse splits+huge losses+scam OTC = GARBAGE

[waterchaser]

Reverse splits are required when a stinky pinky issues too many shares.

CANB is the poster child.

End of story.

[Penny Masters]

Why so many CANB RS's over and over. Did CANB hit the RS limit yet? Looks like another one will be needed to get the price higher for another BS NASDAQ claim. The true value is now in trips after the past RS's.

Sad and hard to watch these schemes play out.

Peace out

[waterchaser]

Why are they losing so much money?
No wonder the PPS is in the toilet.

[skyhawk66]

CANB just keeps Surprising it’s Daily Followers, Amazing!
As Forecasted, Another Record Quarterly Revenue Record for CANB!
Can B Corp. Reports Growth of 51% to $2.9 Million Revenue for Third Quarter 2022, the Highest Quarterly Revenue in Company History

Can B Corp
Tue, November 22, 2022 at 9:30 AM
In this article:

Can B Corp

Led by a Significant Increase in Duramed, Music City Botanical and Botanical Biotech Brands

Adjusted EBITDA Loss Decreased by 25% to $1.5 Million

HICKSVILLE, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company's financial results for the third quarter and nine months ended September 30, 2022.

Key Financial Highlights for Q3 2022

Revenue increased 51% to $2.9 million

Gross profit increased 36% to $1.9 million

Gross margin decreased to 64.3%

Adjusted EBITDA loss decreased by 25% to $1.5 million

Accounts receivable at $7.0 million

Inventory at $2.3 million

Total assets at $16.7 million

Total stockholders’ equity at $4.5 million

Key Financial Highlights for 9 Months Ended September 30, 2022

Revenue increased 130% to $6.0 million

Gross profit increased 59% to $2.8 million

Gross margin decreased to 46.0%

Adjusted EBITDA loss decreased by 15% to $4.5 million

Key Business Highlights for Q3 2022

Signed Manufacturing and Distribution Agreement for Superfood Products with Forever Brands and Brooke Burke via BB Body, Inc.

Consolidated Hemp Division Operations in Colorado

Management Commentary

Marco Alfonsi, Can B’s Chief Executive Officer, stated, “We are thrilled with our tremendous quarterly results, having achieved the highest quarterly revenue in our company history. We generated $2.9 million in quarterly revenue while reducing our cash burn as demonstrated by the 25% decrease in Adjusted EBITDA. Our team made great strides over the past several months integrating and ramping up the various operations we strategically acquired over the past year to complete our vertical processing capabilities.”

Alfonsi concluded, “We had a vision and were confident in the assets we were assembling over the past year. It is great to see all the challenging work pay off and result in accelerating revenue growth and a reduction in cash losses. With our proven manufacturing and distribution capabilities, we are now executing major strategic agreements, such as the recently announced deal with Brooke Burke. Since the end of the quarter, we have started taking orders and shipping Superfood Products with Brooke Burke and are very excited about the early demand and results. Can B is now a full-service hemp-derived cannabinoid company that can facilitate servicing large box retailers, boutique vape and smoke stores, and strategic partners.”

Manufacturing and Distribution Agreement for Superfoods Products with Forever Brands and Brooke Burke via BB Body, Inc.

The initial 3-year worldwide agreement covers the sale, manufacturing, and distribution of Superfoods and related nutritional products. Can B subsidiaries Imbibe Wellness Solutions is the exclusive direct-to-consumer seller of the products and Pure Health Products is a manufacturer and distributor of the products. The products will be marketed under the Longevity by Brooke Burke trademarks and brand. The partnership includes a powdered drink superfood mix, an all-natural metabolic energy drink, and other products that may be mutually agreed from time to time.

Brooke Burke, an American television personality, fitness personality, author, actress, and businessperson, will market, endorse, and promote the products as a monthly online subscription model under her company BB Body, Inc.

Subsequent to the end of the third quarter, the product launched.

Financial Results for the Three Months Ended September 30, 2021:

Revenue: For the three months ended September 30, 2022, revenue was $2.9 million, an increase of $1.0 million, or 51%, compared with $1.9 million for the three months ended September 30, 2021. The increase is due to the ` winddown of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound devices associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase of sales compared to 2021 of approximately $1.5 million.

Gross Profit: For the three months ended September 30, 2022, gross profit was $1.9 million, an increase of $0.5 million, or 36%, compared with $1.4 million for the three months ended September 30, 2021. The resulting gross margin was 64.3%, compared with 71.7% for the same quarter last year.

Total Operating Expenses: For the three months ended September 30, 2022, total operating expenses were $8.7 million, an increase of $4.8 million, or 223%, compared with $3.9 million for the same quarter last year. The increase in operating expenses was primarily due to the non-cash stock-based compensation expense of $4.5 million and $0.8 million of other non-cash and non-recurring one-time items.

Operating Loss: For the three months ended September 30, 2022, operating loss was $6.8 million, an increase of $4.3 million, or 271%, compared with an operating loss of $2.5 million for the same quarter last year.

Adjusted EBITDA Loss: For the three months ended September 30, 2022, Adjusted EBITDA loss was $1.5 million, a decrease of $0.5 million, or 25%, compared with an Adjusted EBITDA loss of $2.0 million for the same period last year, after deducting non-cash and one-time expenses.

Net Loss: For the three months ended September 30, 2022, the net loss was $6.9 million, or ($1.98) per share, compared with a net loss of $3.2 million, or a net loss of ($1.61) per share, for the three months ended September 30, 2021.

Financial Results for the Nine Months Ended September 30, 2022:

Revenue: For the nine months ended September 30, 2022, revenue was $6.0 million, an increase of $3.4 million, or 130%, compared with $2.6 million for the same period last year. The increase is due to the winddown of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound devices associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase of sales compared to 2021 of approximately $2.2 million.

Gross Profit: For the nine months ended September 30, 2022, gross profit was $2.8 million, an increase of $1.0 million, or 59%, compared with $1.7 million for the same period last year. The resulting gross margin was 46%, compared with 66% for the same period last year.

Total Operating Expenses: For the nine months ended September 30, 2022, total operating expenses were $14.3 million, an increase of $5.7 million, or 243%, compared with $8.6 million for the same period last year. The increase in operating expenses was primarily due to the non-cash stock-based compensation expense of $5.1 million.

Operating Loss: For the nine months ended September 30, 2022, operating loss was $11.6 million, an increase of $4.7 million, compared with an operating loss of $6.9 million for the same period last year.

Adjusted EBITDA Loss: For the nine months ended September 30, 2022, Adjusted EBITDA loss was $4.5 million, a decrease of $0.8 million, or 15%, compared with an Adjusted EBITDA loss of $5.3 million for the same period last year, after deducting non-cash and one-time expenses.

Net Loss: For the nine months ended September 30, 2022, net loss was $12.0 million, or ($3.56) per share, compared with $8.2 million, or ($5.39) per share, for the same period last year.

About Can B Corp.

Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp-derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high-quality products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

[waterchaser]

CANB LOSS FOR 9 mos 2022 $12,024,759.
(that’s 12 MILLION DOLLARS)

https://www.otcmarkets.com/filing/conv_pdf?id=16214672&guid=AfG-keOlfywfJth

The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of assets and liquidation of liabilities in a normal course of business. As of September 30, 2022, the Company had cash and cash equivalents of $34,471 and negative working capital of $2,205,209. For the nine months ended September 30, 2022 and 2021, the Company had incurred losses of $12,024,759 and $8,152,487, respectively. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.

[skyhawk66]

CANB, doing just fine, 2nd Outstanding Record Breaking Quarter are Factual Information.
Looks like the going out of business Fiasco has reached an end after 4 years, lol.
Great to See the 24 hour dedication for us CANB followers will pay off soon.
CANB….2023 and Beyond.

[Penny Masters]

LOL,,,, CANB shares are in strong hands. That was a good one and made me laugh. The shares are actually almost worth nothing from the multi RS's they pulled on share holders.

Good luck on the next as this pig is done.

Peace out